Revenue from contracts with customers |
12 Months Ended | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||
| Disclosure of disaggregation of revenue from contracts with customers [abstract] | |||||||||||||||||||||||||||||||||||||
| Revenue from contracts with customers |
Note 4 — Revenue from contracts with customers Disaggregation of revenue from contracts with customers The principal activities of the Company for the years ended March 31, 2023 and 2022 were as follows:
There were revenues of $8,561 and nil for the year ended March 31, 2023 and 2022, respectively. For the year ended March 31, 2023, 100% of the revenue derives from the Company’s ViraxClear test distribution. Accounting policies and significant judgments Management does not consider there to be any significant judgments or estimates in the revenue recognition for the years ended March 31, 2023 and 2022. |
||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for revenue from contracts with customers. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|